Deputy Director , Division of Cancer Prevention, National Cancer Institute, National Institutes of Health
Dr. Lori Minasian, a medical oncologist, is the Deputy Director for the Division of Cancer Prevention at the NCI. She is a leader in NCI clinical trials, first leading the NCI’s Community Clinical Oncology Program (a community-based clinical trials program) for over 15 years, and then supporting a variety of the processes in the restructuring of the NCI’s clinical trials programs. She has facilitated the development of cancer prevention and symptom management clinical trials and the incorporation of patient reported outcomes in cancer clinical trials. Dr. Minasian is one of the senior leaders in the development of the NCI’s Patient Reported Outcomes version of the CTCAE. She initiated an NCI funded consortium of multi-disciplinary teams to develop new methos for analyzing patient reported outcomes to better define patient tolerability in cancer clinical trials. She participated in the Lancet Haematology Commission on modernizing the assessment and reporting of adverse events in haematologic malignancies. In addition to her administrative position, she participates in the NCI’s Women’s Malignancy Clinic seeing patients, supervising fellows and participating in the development and implementation of clinical trials using novel agents. Dr. Minasian earned a Medical Degree from the George Washington University School of Medicine in Washington, D.C. She completed a fellowship in Medical Oncology at the Memorial Sloan-Kettering Cancer Center.